LDS/Medical Tests/Cystic Fibrosis (CFTR) Gene Mutation Analysis

Cystic Fibrosis (CFTR) Gene Mutation Analysis

Cystic Fibrosis (CF) is an autosomal recessive progressive disease with the highest prevalence in Caucasians and the Ashkenazi Jewish population. Although other ethnicities are not spared from this disease, incidences are less frequent. Estimated pre-test and post-test carrier risk varies from ethnicity and ranges from 1 in 25 for whites to 1 in 65 for African Americans with the risk reduction after screening to 1 in 800 for whites and 1 in 229 for African Americans (see table below). Overall, the prevalence of CF is 1 in 2500-3000 live births. For couples in whom both individuals are CF carriers, the risk for an affected child is 1 in 4.

CF is caused by mutation in CFTR (cystic fibrosis transmembrane conductance regulator) gene, which is located on the long arm of chromosome 7. Over 1000 mutations have been identified in the CFTR gene. The CFTR protein functions in electrolyte (especially chloride) transport across the apical membrane of epithelial cells affecting mainly organs lined with these cells. Therefore, an abnormal CFTR protein will result in defective electrolyte and chloride ion transport in the epithelial cells of the respiratory, gastrointestinal, and reproductive tracts. CF is characterized by viscous mucus in the lungs with involvement of digestive and reproductive systems as well as sweat glands (excess salt loss).

CF mutation testing is performed for the purpose of diagnosis of CF or to determine carrier status. Indications include clinical suspicion either of CF (mild, severe, or atypical forms), CBAVD, or idiopathic chronic pancreatitis. The American College of Obstetricians and Gynecologists (ACOG) and the American College of Medical Genetics (ACMG) recommend offering testing for 25 common CFTR mutations to all women currently planning a pregnancy or seeking prenatal care. This helps identify carriers and thereby informs their reproductive choices. Each of the 25 mutations in the ACOG/ACMG panel has an allele frequency of 0.1% or greater in the general, pan-ethnic U.S. population.

Individuals with two identified mutations, one in each gene, have CF. Individuals who do not have a mutation identifiable by this assay may still be a carrier. A negative carrier test lowers the individual's risk of being a carrier and having a child with Cystic Fibrosis (see table below) but does not eliminate the risk, as other mutations might be present not tested by the ACOG’s recommended panel.

Ethnic Group Detection Rate Carrier Risk Before Testing Carrier Risk After Negative Test
Ashkenazi Jewish 97% 1 in 25 ~1 in 800
European Caucasian 90% 1 in 25 ~1 in 240
African American 72% 1 in 65 ~1 in 229
Hispanic American 57% 1 in 46 ~1 in 108
Asian American *** 1 in 90 ?

 

Carrier Screen:

  • Revision of carrier risk for an individual with a positive family history of CF
  • Revision of carrier risk for an individual whose partner has a positive family history of CF
  • Revision of a carrier risk for an individual with a negative family history who is planning a pregnancy # Diagnostic Testing:
  • Diagnosis of CF in a symptomatic newborn
  • Diagnosis of CF in a neonate with equivocal clinical findings
  • Identification of familial mutation in an affected patient
  • Identification of mutations in an infertile male with congenital bilateral absence of the vas deferens (CBAVD)

Positive in:

  • Carriers
  • Affected with CF
  • CBAVD

Diagnosis: Detection of 2 mutant alleles in conjunction with positive clinical findings or family history is consistent with CF. Failure to detect 1 or more mutant alleles in a symptomatic patient, however, does not exclude a diagnosis of CF. Additional testing or sweat chloride testing should be performed in all suspected CF cases.

Carrier Detection: The presence of a single CF mutation in an asymptomatic individual identifies that person as a carrier. Absence of a CF mutation significantly reduces, but does not eliminate, the risk of being a carrier. The residual risk of being a carrier (i.e., of having a CF mutation not screened for in this assay) is influenced by the individual's clinical and family history and ethnicity. If clinically indicated, additional testing is available.

Note: Pre-analytic clinical information is required in order to interpret the test results. Specifically, the test indication (carrier screen, diagnostic testing), the patient’s ethnic background, and family history of CF should be detailed on the Molecular Genetics Requisition Form or on electronic order. In some cases, it may be necessary to test an additional family member in order to interpret a negative result for a patient with a positive family history of this disease. Appropriate counseling should follow CF mutation analysis so the patient fully understands the residual risk associated with a negative result and the reproductive ramifications of a positive result.

Negative for the CFTR mutations analyzed
 

 

Multiplex PCR-amplification refractory mutation system (PCR-ARMS) and Invader/InPlex™ technology (ARMS), PCR Chip Array ARMS based technology; PCR Invader based technology, PCR sequencing technology.

Whole blood. EDTA (Lavender top tube), Citrated (blue top tube).

  • Ambient: 1-2 days
  • Refrigerated: 7 days
  • Frozen for longer storage
Chloride Sweat Testing, Immunoreactive Trypsin Test, Complete CFTR Genetic Testing by Sequencing, Respiratory Culture, Amylase, Lipase, Semen analysis.
3-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login